AR104935A1 - Formas cristalinas de un inhibidor de histona deacetilasa - Google Patents

Formas cristalinas de un inhibidor de histona deacetilasa

Info

Publication number
AR104935A1
AR104935A1 ARP160101702A ARP160101702A AR104935A1 AR 104935 A1 AR104935 A1 AR 104935A1 AR P160101702 A ARP160101702 A AR P160101702A AR P160101702 A ARP160101702 A AR P160101702A AR 104935 A1 AR104935 A1 AR 104935A1
Authority
AR
Argentina
Prior art keywords
deacetilasa
histona
inhibitor
crystal forms
crystal
Prior art date
Application number
ARP160101702A
Other languages
English (en)
Inventor
Liu Gui
Seyedi Farzaneh
H Van Duzer John
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of AR104935A1 publication Critical patent/AR104935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una forma cristalina de 2-((2-clorofenil)(fenil)amino)-N-(7-(hidroxiamino)-7-oxoheptil)pirimidin-5-carboxamida.
ARP160101702A 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa AR104935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172629P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
AR104935A1 true AR104935A1 (es) 2017-08-23

Family

ID=56178492

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101702A AR104935A1 (es) 2015-06-08 2016-06-08 Formas cristalinas de un inhibidor de histona deacetilasa

Country Status (6)

Country Link
US (1) US10464906B2 (es)
EP (1) EP3303306B1 (es)
JP (1) JP6816036B2 (es)
AR (1) AR104935A1 (es)
TW (1) TW201718516A (es)
WO (1) WO2016200919A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
JP6873053B2 (ja) 2015-06-08 2021-05-19 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． タンパク質脱アセチル化阻害剤の製造方法
TW201803594A (zh) * 2016-06-09 2018-02-01 達納-法伯癌症協會 Hdac抑制劑與bet抑制劑之使用方法及醫藥組合
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用
EP3544600A4 (en) 2016-11-23 2020-06-17 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
ES2294190T3 (es) 2001-11-01 2008-04-01 Janssen Pharmaceutica N.V. Derivados de amida como inhibidores de la glucogeno sintasa quinasa 3-beta.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP4993374B2 (ja) 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
US20070155730A1 (en) 2005-08-26 2007-07-05 Methylgene, Inc. Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase
CN101400362B (zh) 2006-02-14 2016-10-12 哈佛大学校长及研究员协会 双官能组蛋白去乙酰化酶抑制剂
WO2007130429A2 (en) 2006-05-03 2007-11-15 The President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
WO2009104696A1 (ja) 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
WO2011084991A2 (en) 2010-01-08 2011-07-14 President And Fellows Of Harvard College Fluorinated hdac inhibitors and uses thereof
DK2526093T3 (en) * 2010-01-22 2016-11-14 Acetylon Pharmaceuticals Inc Reverse amide compounds as proteindeacetylasehæmmere and methods of use thereof
AU2011255281A1 (en) 2010-05-21 2013-01-10 Sloan-Kettering Institute For Cancer Research Selective HDAC inhibitors
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
KR20130115300A (ko) 2010-11-16 2013-10-21 에이스틸론 파마수티컬스 인코포레이티드 단백질 탈아세틸화 효소 억제제로서 피리미딘 하이드록시 아미드 화합물 및 그의 사용방법
JP6169076B2 (ja) 2011-07-20 2017-07-26 ザ ジェネラル ホスピタル コーポレイション 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤
WO2013158984A1 (en) 2012-04-19 2013-10-24 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
JP2015533173A (ja) 2012-10-12 2015-11-19 トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア タンパク質脱アセチル化酵素阻害剤としてのピリミジンヒドロキシアミド化合物およびその使用方法
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014197471A1 (en) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
EP3046559A4 (en) 2013-09-20 2017-03-22 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
JP2016536354A (ja) 2013-10-10 2016-11-24 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ
ES2862126T3 (es) 2013-10-10 2021-10-07 Acetylon Pharmaceuticals Inc Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
CR20160200A (es) 2013-10-11 2016-08-29 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores
JP2016534069A (ja) 2013-10-24 2016-11-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｄａｃ６阻害剤での多嚢胞性疾患の治療
EP3076973B1 (en) 2013-12-03 2020-04-29 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
ES2936812T3 (es) 2013-12-20 2023-03-22 Acetylon Pharmaceuticals Inc Biomarcadores de histona desacetilasa 6 (HDAC6) en mieloma múltiple
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
MX2017000307A (es) 2014-07-07 2017-11-23 Acetylon Pharmaceuticals Inc Tratamiento de leucemia con inhibidores de histona deacetilasa.
EP3204006A4 (en) 2014-10-08 2018-04-04 Regenacy Pharmaceuticals, LLC Induction of gata2 by hdac1 and hdac2 inhibitors
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
CN107835810A (zh) 2014-12-12 2018-03-23 瑞格纳西制药有限公司 作为hdac1/2抑制剂的哌啶衍生物
WO2016168647A1 (en) 2015-04-17 2016-10-20 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibotrs
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
JP6873053B2 (ja) 2015-06-08 2021-05-19 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． タンパク質脱アセチル化阻害剤の製造方法

Also Published As

Publication number Publication date
JP6816036B2 (ja) 2021-01-20
EP3303306A1 (en) 2018-04-11
JP2018516946A (ja) 2018-06-28
US10464906B2 (en) 2019-11-05
US20170001965A1 (en) 2017-01-05
EP3303306B1 (en) 2020-02-12
WO2016200919A1 (en) 2016-12-15
TW201718516A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
MA42606A (fr) Sels d'un inhibiteur de lsd1
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
AR104935A1 (es) Formas cristalinas de un inhibidor de histona deacetilasa
DK3601283T3 (da) Kondenseret imidazo-piperidin-JAK-inhibitorforbindelse
DK3746424T3 (da) Erbb/btk-inhibitorer
DK3713919T3 (da) Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid
AR095039A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
DK3261639T3 (da) Substituerede pyrazolforbindelser som serinproteaseinhibitorer
ECSP17054980A (es) Inhibidores selectivos de bace1
DK3774817T3 (da) Bcl6-hæmmere
ES2975690T3 (es) Inhibidores de BCL6 derivados de benzimidazolona
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
DK3470409T3 (da) Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
DK3513617T3 (da) Håndtering af PDCP under genetablering af forbindelse
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
MA49006A (fr) Inhibiteurs d'ip6k

Legal Events

Date Code Title Description
FB Suspension of granting procedure